Trident Texofab Faces Mixed Performance Amid High Debt and Decreased Promoter Holding

May 06 2025 08:41 AM IST
share
Share Via
Trident Texofab has recently adjusted its evaluation, reflecting shifts in underlying trends and technical indicators. The company reported positive quarterly financial results, including net sales of Rs 31.69 crore, but faces challenges with high debt levels and declining promoter holdings, despite strong market performance over the past year.
Trident Texofab, a microcap company in the trading industry, has recently undergone an evaluation adjustment that reflects changes in its underlying trends. The stock's technical indicators have shown a shift, with the technical trend moving from bullish to mildly bullish. This adjustment comes amid a backdrop of mixed performance metrics, including a notable return of 327.01% over the past year, despite a decline in operating profit growth over the last five years.

The company has reported positive financial results for the quarter ending December 2024, with net sales reaching Rs 31.69 crore and a profit after tax of Rs 1.95 crore. However, it continues to grapple with high debt levels, as indicated by a debt-to-equity ratio averaging 2.40 times, which raises concerns about its long-term fundamental strength. Additionally, the return on equity stands at 9.41%, suggesting limited profitability relative to shareholders' funds.

Promoter holding has also seen a decrease, now at 35.54%. Despite these challenges, Trident Texofab has demonstrated market-beating performance in both the near and long term, outperforming the BSE 500 index over various periods.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Why is Trident Texofab falling/rising?
Dec 12 2025 01:10 AM IST
share
Share Via
Is Trident Texofab overvalued or undervalued?
Dec 05 2025 08:41 AM IST
share
Share Via
Is Trident Texofab technically bullish or bearish?
Dec 04 2025 08:47 AM IST
share
Share Via
How has been the historical performance of Trident Texofab?
Dec 03 2025 10:55 PM IST
share
Share Via
Is Trident Texofab overvalued or undervalued?
Nov 19 2025 08:10 AM IST
share
Share Via